Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (68 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  V.TLT.WT | TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > Question for the Pharma Savvy
View:
Post by plantrader on Jun 12, 2024 6:58pm

Question for the Pharma Savvy

I know some of you are fairly insightful about this industry. This question is for you. Forget high hopes and theoretical future potential for a moment, because there are a lot of "ifs" and a lot of execution and delivery that hasn't happened yet, in the bigger picture right?

It seems that what we do have is some impressive technology and some very encouraging partial clinical trial data. And a whole bunch of very compelling pre-clinical data. I'm wondering if any of you have a feel for what the company could be worth right now? Not based on a bunch of maybes/ifs, but based on the current set of knowns and unknowns. And without BTD. Or is the company only a buyout candidate after BTD, because that effectively removes some of the unknowns? I'm wondering if this is why the market shuns this company, not enough officially endorsed progress (FDA)? Too high % chance of failure at this point?
Comment by socksnblonds642 on Jun 12, 2024 7:24pm
I think you nailed what most of us are thinking. The  value right now is  simply SP X shares outstanding. That's market capitalization. No real assets to calculate in. Warrants have no intrinsic value since SP is below the exercise price.  The last few PR's have a lot of potential but for now this info is immaterial. They are just saving mice. Mice don't invest. We all ...more  
Comment by StevenBirch on Jun 12, 2024 7:53pm
That is the most negative take you could have of the last few news releases. Of course value is not the stock price but revenue from the cancer division, any possible deals and even approvals from the FDA would add value which they don't have yet. What these news releases do is preview what future value looks like but more importantly it's ammunition to use in making a deal now or in the ...more  
Comment by plantrader on Jun 12, 2024 8:05pm
SB, What's your current value estimate prior to BTD? $100M on unproven potential? Or is it a moot subject without BTD? If yes to the latter, maybe that could explain why the market doesn't react much to the company's statements.
Comment by beenthere on Jun 12, 2024 9:33pm
A great example of how StockHouse " doesn't " work! SB you got 8 likes and as much I agree with what you are saying ..... ....I would like to vote a negative one vote because Iam a realist! I would like SH to allow everyone to vote a positive  +1 or a negative -1 That way the result is more to the actual feelings of the Board's ! IMO
Comment by Alamir1111 on Jun 12, 2024 9:53pm
Pain management  market world vide 72 billion$ TLT share is 1.1milion gross after almost 20 years in business.that is 72 bill÷1.1 million =0.0000000??Nmbic trial started 7 years ago today 68 treated..yes nice updates but no$ . Ithink herpes and ru bcg might get a chance
Comment by Longholder99 on Jun 12, 2024 8:37pm
Kool-aid can turn into Loius XIV Cognac in one NR.  Also drinking Kool-aid today and yesterday. 
Comment by menoalittle on Jun 12, 2024 8:56pm
Drink the kool-aid? Shoot, I have so much u should be serving it... lol.
Comment by N0taP00p on Jun 12, 2024 8:09pm
For many (not all) companies at this stage of development and with so much promise, one would think a $300M to $500 M market cap is very reasonable. At least a dollar+ per share.   The IP is there, the initial results seem to beat or equal the best out there, safety looks good, and all with just one or two treatments.  So what gives?   I think it's a combination of the ...more  
Comment by plantrader on Jun 12, 2024 8:13pm
@Not, thanks for the breakdown, appreciate it. Makes sense.  You're not a poop!
Comment by N0taP00p on Jun 12, 2024 8:27pm
LOL.. Thanks Plantrader. One last thing. Limited VC ecosystem in Toronto/Canada may be another big factor.  They need to pitch this to Mr. Wonderful. Convince him it's a 20 bagger. 
Comment by menoalittle on Jun 12, 2024 8:45pm
1/4 Billion is too cheap (I'd vote against it), but 1/2,Billion in a Merck stock exchange I'd be inclined to accept.  However, 1/2 billion in a cash buyout I'm not so keen on.  Would probably turn that down.
Comment by plantrader on Jun 12, 2024 8:51pm
It probably only matters what the BOD/Mgt votes, right? They'd far outweigh your, or anyone else's, combined votes. I agree though, even as a non-expert... would prefer at least $1B if it's a cash buyout. This is where other posters will scold me that this company is clearly worth several $B.
Comment by Galaxym31 on Jun 12, 2024 9:33pm
Lets see if there are any mid size pharma company that might see a road to get in the ground floor of a new type of treatement that can rise above decades of slash burn and poison . 
Comment by Bigkahuna57 on Jun 12, 2024 10:35pm
Ref: $250M for 33% of the company?  I hope I misread that, and you meant as a buy-in with performance milestone payments for 1 single indication.  A total buyout for the entire portfolio and all future development of the galaxy of cancer indications at one time?  I don't think many would consider that b/c negotiations haven't run the full gammit of valuation possibilities ...more  
Comment by N0taP00p on Jun 12, 2024 11:03pm
Yes, BK. What you said. As a buy in for one indication. That's all they have now.  Future valuation would be based on negotiated potential (based on indications that need to be funded for trials first). End of my speculations.  Back to waiting and watching. 
Comment by Rumpl3StiltSkin on Jun 12, 2024 9:00pm
Poop, I'd like to see Health Canada give them a grant in that $$$$ range. Then Let's see what kind of a real deal Dr. LBiati can get from a Pharma??
Comment by N0taP00p on Jun 12, 2024 9:31pm
I didn't know HCA does grants. Wouldn't that be a conflict of interest? Incremental milestone based acquisition from a larger entity ($3 - $7 - $10) would be par for the course, if and when they do get BTD. Like everyone else, I'm just hoping they get BTD first. After 3 NRs, we all know what's likely to happen in the next few weeks. They are probably out of money about now.
Comment by CancerSlayer on Jun 13, 2024 3:30am
Agree....this exchange, the current cash position & the legacy of Photofrin can all act like anchors on value.  On the bright side, there has been a significant uptick in acquisitions of small/startup biotech companies in the past 6+ months...deals in the On the surface, this company's tech with its base compound (Ruvidar) has much broader potential than many (if not all) of the ...more  
Comment by Tarbaby on Jun 13, 2024 2:16am
TLT was basically a one trick pony until very recently. Investors got tired of waiting for the bladder cancer trial to be completed..and just lost patience.  So the stock just languished. Now suddenly we get a smorgasbord of almost miraculous treatments like... vaccine for blood cancers..Radiation activated Rudivar to kill lung and other cancer...Ru bcg combo for bladder cancer...Rutherrin ...more  
Comment by Gooseybear on Jun 13, 2024 6:22am
Agreed tar baby. If anything in these PR releases is not accurate, someone may go to jail.
Comment by Kingpin68 on Jun 13, 2024 8:22am
Yes Tarbaby, so true.  And let's not forget to add a cream for herpes and laser therapy helmet for Parkinson's.... What a great pipeline. I keep buying at these levels 
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

View the Presentation

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 68 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250